Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: Paving the way for molecular imaging

Cellular Oncology

Volumn 36, Issue 4, 2013, Pages 333-340

  Vermeulen, Jeroen F ^a   Van Der Wall, Elsken ^a   Witkamp, Arjen J ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Ductal carcinoma in situ; Growth factor receptors; Hypoxia; Immunohistochemistry; Invasive breast cancer; Molecular imaging

Indexed keywords

CARBONATE DEHYDRATASE XII; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE TRANSPORTER 1; MAMMAGLOBIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR IMAGING; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84881645930     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0138-4     Document Type: Article

References (37)

1. H. Wong, S. Lau, R. Leung, J. Chiu, P. Cheung, T.T. Wong, R. Liang, R.J. Epstein, T. Yau, Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Med. Oncol. 29(3), 1536-1542 (2012)
2. J.V. Frangioni, In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 7(5), 626-634 (2003)
3. J.V. Frangioni, New technologies for human cancer imaging. J. Clin. Oncol. 26(24), 4012-4021 (2008)
4. G.M. van Dam, G. Themelis, L.M. Crane, N.J. Harlaar, R.G. Pleijhuis, W. Kelder, A. Sarantopoulos, J.S. de Jong, H.J. Arts, A.G. van der Zee, J. Bart, P.S. Low, V. Ntziachristos, Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat. Med. 17(10), 1315-1319 (2011)
5. C. Hirche, D. Murawa, Z. Mohr, S. Kneif, M. Hunerbein, ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res. Treat. 121(2), 373-378 (2010)
6. D. Murawa, C. Hirche, S. Dresel, M. Hunerbein, Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br. J. Surg. 96(11), 1289-1294 (2009)
7. R.G. Pleijhuis, G.C. Langhout, W. Helfrich, G. Themelis, A. Sarantopoulos, L.M. Crane, N.J. Harlaar, J.S. de Jong, V. Ntziachristos, G.M. van Dam, Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms. Eur. J. Surg. Oncol. 37(1), 32-39 (2011)
8. R.G. Pleijhuis, M. Graafland, J. de Vries, J. Bart, J.S. de Jong, G.M. van Dam, Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann. Surg. Oncol. 16(10), 2717-2730 (2009)
9. K. Park, S. Han, H.J. Kim, J. Kim, E. Shin, HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48(6), 702-707 (2006)
10. R.M. Tamimi, H.J. Baer, J. Marotti, M. Galan, L. Galaburda, Y. Fu, A.C. Deitz, J.L. Connolly, S.J. Schnitt, G.A. Colditz, L.C. Collins, Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 10(4), R67 (2008)
11. B.B. Bryan, S.J. Schnitt, L.C. Collins, Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 19(5), 617-621 (2006)
12. P. Meijnen, J.L. Peterse, N. Antonini, E.J. Rutgers, M.J. van de Vijver, Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br. J. Cancer 98(1), 137-142 (2008)
13. D.J. Dabbs, M. Chivukula, G. Carter, R. Bhargava, Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod. Pathol. 19(11), 1506-1511 (2006)
14. S.E. Clark, J. Warwick, R. Carpenter, R.L. Bowen, S.W. Duffy, J.L. Jones, Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br. J. Cancer 104(1), 120-127 (2011)
15. A.F. Logullo, S. Nonogaki, F.S. Pasini, C.A. Osorio, F.A. Soares, M.M. Brentani, Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol. Rep. 23(2), 313-320 (2010)
16. K. Lindemann, J. Resau, J. Nahrig, E. Kort, B. Leeser, K. Annecke, A. Welk, J. Schafer, G.F. Vande Woude, E. Lengyel, N. Harbeck, Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 51(1), 54-62 (2007)
17. M. Gotte, C. Kersting, I. Radke, L. Kiesel, P. Wulfing, An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9(1), R8 (2007)
18. J.F. Vermeulen, A.S. van Brussel, P. van der Groep, F.H. Morsink, P. Bult, E. van der Wall, P.J. van Diest, Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer 12(1), 240 (2012)
19. C.C. Wykoff, N. Beasley, P.H. Watson, L. Campo, S.K. Chia, R. English, J. Pastorek, W.S. Sly, P. Ratcliffe, A.L. Harris, Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158(3), 1011-1019 (2001)
20. R. Bos, H. Zhong, C.F. Hanrahan, E.C. Mommers, G.L. Semenza, H.M. Pinedo, M.D. Abeloff, J.W. Simons, P.J. van Diest, E. van der Wall, Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93(4), 309-314 (2001)
21. C.L. Chen, J.S. Chu, W.C. Su, S.C. Huang, W.Y. Lee, Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch. 457(1), 53-61 (2010)
22. M. Schmidt, H.U. Voelker, M. Kapp, M. Krockenberger, J. Dietl, U. Kammerer, Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J. Cancer Res. Clin. Oncol. 136(2), 219-225 (2010)
23. R. Holland, J.L. Peterse, R.R. Millis, V. Eusebi, D. Faverly, M.J. van de Vijver, B. Zafrani, Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol. 11(3), 167-180 (1994)
24. C.W. Elston, I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5), 403-410 (1991)
25. J. Packeisen, E. Korsching, H. Herbst, W. Boecker, H. Buerger, Demystified.tissue microarray technology. Mol. Pathol. 56(4), 198-204 (2003)
26. P.J. van Diest, No consent should be needed for using leftover body material for scientific purposes. For. BMJ 325(7365), 648-651 (2002)
27. M. Koppe, F. Schaijk, J. Roos, P. Leeuwen, K.H. Heider, H. Kuthan, R. Bleichrodt, Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. Cancer Biother. Radiopharm. 19(6), 720-729 (2004)
28. J.F. Vermeulen, A.S. van Brussel, A. Adams, W.P. Mali, E. van der Wall, P.J. van Diest, P.W. Derksen, Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma In Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study. Mol. Imaging Biol. 15(3), 290-298 (2013)
29. D.H. Barnett, S. Sheng, T.H. Charn, A. Waheed, W.S. Sly, C.Y. Lin, E.T. Liu, B.S. Katzenellenbogen, Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res. 68(9), 3505-3515 (2008)
30. M. van Oosten, L.M. Crane, J. Bart, F.W. van Leeuwen, G.M. van Dam, Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. Transl. Oncol. 4(2), 71-82 (2011)
31. A. Bunschoten, T. Buckle, N.L. Visser, J. Kuil, H. Yuan, L. Josephson, A.L. Vahrmeijer, F.W. van Leeuwen, Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting alphavbeta3 integrin. Chembiochem 13(7), 1039-1045 (2012)
32. O. Jacobson, L. Zhu, G. Niu, I.D. Weiss, L.P. Szajek, Y. Ma, X. Sun, Y. Yan, D.O. Kiesewetter, S. Liu, X. Chen, MicroPET imaging of integrin alphavbeta3 expressing tumors using 89Zr-RGD peptides. Mol. Imaging Biol. 13(6), 1224-1233 (2011)
33. Y. Zhou, G. Shao, S. Liu, Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin alpha(v)beta(3)-Targeted Radiotracer(99m)Tc-3P- RGD(2). Theranostics 2(6), 577-588 (2012)
34. M.S. Gee, R. Upadhyay, H. Bergquist, H. Alencar, F. Reynolds, M. Maricevich, R. Weissleder, L. Josephson, U. Mahmood, Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 248(3), 925-935 (2008)
35. S.B. Lee, M. Hassan, R. Fisher, O. Chertov, V. Chernomordik, G. Kramer-Marek, A. Gandjbakhche, J. Capala, Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin. Cancer Res. 14(12), 3840-3849 (2008)
36. L. Sampath, S. Kwon, S. Ke, W. Wang, R. Schiff, M.E. Mawad, E.M. Sevick-Muraca, Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J. Nucl. Med. 48(9), 1501-1510 (2007)
37. K. Sano, M. Mitsunaga, T. Nakajima, P.L. Choyke, H. Kobayashi, In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. Breast Cancer Res. 14(2), R61 (2012)